TrialCurveTARGIT-A (long-term follow-up): reconstructed Kaplan–Meier curves
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | BMJ. 2020 Aug 19;370:m2836. doi: 10.1136/bmj.m2836 |
|---|---|
| DOI | 10.1136/bmj.m2836 |
| Registry | NCT00983684 |
| Phase | Phase 3 |
| Conditions | Invasive Breast Cancer, Breast Cancer |
| Interventions | Intrabeam, Post-operative radiotherapy |
| Sponsor | University College, London |
| Enrolment | 3451 |
| Source licence | Figure published under CC BY 4.0 |
Local recurrence-free survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 97%; EBRT 97%. Hazard ratio EBRT vs TARGIT 0.86 (95% CI 0.68–1.08).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 155 | not reached |
| EBRT | 1158 | 134 | not reached |
- EBRT vs TARGIT: reconstructed HR 0.86 (95% CI 0.68–1.08)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 99.7% | 99.7% |
| 2 yr | 98.5% | 98.3% |
| 3 yr | 97.3% | 96.9% |
| 5 yr | 94.3% | 94.5% |
| 7 yr | 90.4% | 92.6% |
| 10 yr | 84.4% | 86.4% |
Checks against the published figure
- hazard ratio: printed 1.13, reconstructed 1.16 pass
Invasive local recurrence-free survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 97%; EBRT 97%. Hazard ratio EBRT vs TARGIT 0.94 (95% CI 0.74–1.19).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 144 | not reached |
| EBRT | 1158 | 135 | not reached |
- EBRT vs TARGIT: reconstructed HR 0.94 (95% CI 0.74–1.19)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 99.5% | 99.5% |
| 2 yr | 98.5% | 98.1% |
| 3 yr | 97.3% | 96.7% |
| 5 yr | 94.7% | 94.3% |
| 7 yr | 91.2% | 92.6% |
| 10 yr | 85.5% | 85.8% |
Checks against the published figure
- hazard ratio: printed 1.04, reconstructed 1.07 pass
Mastectomy-free survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 95%; EBRT 95%. Hazard ratio TARGIT vs EBRT 0.95 (95% CI 0.76–1.17).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 162 | not reached |
| EBRT | 1158 | 171 | not reached |
- TARGIT vs EBRT: reconstructed HR 0.95 (95% CI 0.76–1.17)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 97.1% | 96.9% |
| 2 yr | 96.0% | 95.9% |
| 3 yr | 95.0% | 94.8% |
| 5 yr | 92.4% | 91.9% |
| 7 yr | 89.1% | 89.3% |
| 10 yr | 83.9% | 83.0% |
Checks against the published figure
- hazard ratio: printed 0.96, reconstructed 0.946 pass
Distant disease-free survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 97%; EBRT 97%. Hazard ratio TARGIT vs EBRT 0.87 (95% CI 0.68–1.10).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 126 | not reached |
| EBRT | 1158 | 144 | not reached |
- TARGIT vs EBRT: reconstructed HR 0.87 (95% CI 0.68–1.10)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 99.3% | 99.1% |
| 2 yr | 98.3% | 97.9% |
| 3 yr | 97.1% | 96.7% |
| 5 yr | 94.9% | 94.2% |
| 7 yr | 91.5% | 90.8% |
| 10 yr | 87.4% | 85.1% |
Checks against the published figure
- hazard ratio: printed 0.88, reconstructed 0.867 pass
Breast cancer specific survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 98%; EBRT 99%. Hazard ratio EBRT vs TARGIT 0.90 (95% CI 0.63–1.29).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 63 | not reached |
| EBRT | 1158 | 56 | not reached |
- EBRT vs TARGIT: reconstructed HR 0.90 (95% CI 0.63–1.29)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 99.8% | 99.8% |
| 2 yr | 99.3% | 99.3% |
| 3 yr | 98.5% | 98.6% |
| 5 yr | 97.4% | 97.4% |
| 7 yr | 96.0% | 96.5% |
| 10 yr | 93.5% | 94.0% |
Checks against the published figure
- hazard ratio: printed 1.12, reconstructed 1.11 pass
Non-breast cancer survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 99%; EBRT 98%. Hazard ratio TARGIT vs EBRT 0.61 (95% CI 0.42–0.89).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 43 | not reached |
| EBRT | 1158 | 70 | not reached |
- TARGIT vs EBRT: reconstructed HR 0.61 (95% CI 0.42–0.89)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 99.8% | 99.8% |
| 2 yr | 99.3% | 99.1% |
| 3 yr | 98.8% | 98.5% |
| 5 yr | 97.9% | 97.3% |
| 7 yr | 97.2% | 95.8% |
| 10 yr | 95.7% | 92.3% |
Checks against the published figure
- hazard ratio: printed 0.59, reconstructed 0.608 pass
Overall survival
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: TARGIT not reached; EBRT not reached. Survival at 3 years: TARGIT 98%; EBRT 98%. Hazard ratio TARGIT vs EBRT 0.83 (95% CI 0.64–1.07).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 106 | not reached |
| EBRT | 1158 | 126 | not reached |
- TARGIT vs EBRT: reconstructed HR 0.83 (95% CI 0.64–1.07)
Landmark survival (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 99.7% | 99.7% |
| 2 yr | 99.0% | 98.6% |
| 3 yr | 97.9% | 97.6% |
| 5 yr | 96.1% | 95.2% |
| 7 yr | 93.1% | 92.7% |
| 10 yr | 89.0% | 86.5% |
Checks against the published figure
- hazard ratio: printed 0.82, reconstructed 0.83 pass
Breast cancer mortality — TARGIT-A trial
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years: TARGIT 1%; EBRT 1%. Hazard ratio EBRT vs TARGIT 0.92 (95% CI 0.64–1.31).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 62 | not reached |
| EBRT | 1158 | 56 | not reached |
- EBRT vs TARGIT: reconstructed HR 0.92 (95% CI 0.64–1.31)
Cumulative incidence (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 0.0% | 0.1% |
| 2 yr | 0.2% | 0.9% |
| 3 yr | 0.9% | 1.4% |
| 5 yr | 2.1% | 2.5% |
| 7 yr | 3.9% | 3.2% |
| 10 yr | 6.6% | 6.3% |
Checks against the published figure
- hazard ratio: printed 1.12, reconstructed 1.09 pass
Non-breast cancer mortality — TARGIT-A trial
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years: TARGIT 1%; EBRT 1%. Hazard ratio TARGIT vs EBRT 0.58 (95% CI 0.39–0.85).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 41 | not reached |
| EBRT | 1158 | 70 | not reached |
- TARGIT vs EBRT: reconstructed HR 0.58 (95% CI 0.39–0.85)
Cumulative incidence (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 0.2% | 0.3% |
| 2 yr | 0.5% | 0.8% |
| 3 yr | 0.9% | 1.4% |
| 5 yr | 1.5% | 2.6% |
| 7 yr | 2.7% | 4.2% |
| 10 yr | 4.0% | 7.6% |
Checks against the published figure
- hazard ratio: printed 0.59, reconstructed 0.578 pass
Overall mortality — TARGIT-A trial
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years: TARGIT 2%; EBRT 3%. Hazard ratio TARGIT vs EBRT 0.81 (95% CI 0.62–1.05).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| TARGIT | 1140 | 103 | not reached |
| EBRT | 1158 | 126 | not reached |
- TARGIT vs EBRT: reconstructed HR 0.81 (95% CI 0.62–1.05)
Cumulative incidence (reconstructed)
| Time | TARGIT | EBRT |
|---|---|---|
| 1 yr | 0.2% | 0.4% |
| 2 yr | 0.6% | 1.7% |
| 3 yr | 1.9% | 2.9% |
| 5 yr | 4.0% | 5.3% |
| 7 yr | 6.7% | 7.2% |
| 10 yr | 10.3% | 13.2% |
Checks against the published figure
- hazard ratio: printed 0.82, reconstructed 0.807 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/targit-a-long-term-follow-up-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/targit-a-long-term-follow-up-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: BMJ. 2020 Aug 19;370:m2836. doi: 10.1136/bmj.m2836 doi:10.1136/bmj.m2836. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/targit-a-long-term-follow-up
Report a problem with these data
Related trials
- PEONY: Disease-free survival (DFS); Event-free survival (EFS)
- SECRAB: Disease free survival; Local recurrence; Loco-regional in-field recurrence; Overall surviv
- PERSEPHONE: Disease-free survival; Overall survival
- CirCe01: Overall survival; Progression-free survival
- TROIKA (final analysis): Event free survival
- DATA (10-year update): Adapted breast cancer-free interval (cumulative incidence of breast cancer events); Adapte
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials